Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06243510 · ClinicalTrials.gov registry record · NA
Comparison of Apixaban Versus Enoxaparin
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 126
- Enrollment target
NCT06243510 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 126 participants.
The verdict
NCT06243510, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 126 participants
- Enrollment target
Study Summary
The goal of this randomized trial is to compare bladder cancer patient experiences taking prophylactic anticoagulation at home after surgery to remove their bladder. The main questions it aims to answer are: * Are patients equally adherent to apixaban as they are enoxaparin? Why or why not? * Do patients prefer apixaban or enoxaparin? * What is the typical patient cost to take apixaban vs enoxaparin after surgery? Participants will be randomized to receive a prescription for either enoxaparin or apixaban which they will then fill themselves and self-administer at home until post-operative day 30. They will receive phone calls from study coordinators at days 30 and 90 to complete questionaries over the phone to assess trial outcomes.
Interventions
- OTHER apixaban
- OTHER enoxaparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2023-11-24 |
| Est. Completion | 2026-03-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06243510
The ClinicalTrials.gov registry entry for NCT06243510 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which apixaban is the first listed.
NCT06243510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06243510 about?
NCT06243510 is a clinical study titled "Comparison of Apixaban Versus Enoxaparin". The goal of this randomized trial is to compare bladder cancer patient experiences taking prophylactic anticoagulation at home after surgery to remove their bladder. The main questions it aims to answer are: * Are patients equally adherent to apixaban as they are enoxaparin? Why or why not? * Do pa...
What is the current status of trial NCT06243510?
This trial is currently completed. It is a NA study. The enrollment target is 126 participants. The study started on 2023-11-24. Estimated completion is 2026-03-30.
What interventions are being tested in trial NCT06243510?
The interventions under investigation include: apixaban (OTHER), enoxaparin (OTHER).
Who is sponsoring clinical trial NCT06243510?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.